VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+12.86%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$158M
AUM Growth
-$7.14M
(-4.3%)
Cap. Flow
-$21.5M
Cap. Flow
% of AUM
-13.64%
Top 10 Holdings %
Top 10 Hldgs %
5.64%
Holding
474
New
40
Increased
153
Reduced
231
Closed
49
Top Buys
| 1 |
Expedia Group
EXPE
|
$932K |
| 2 |
Prologis
PLD
|
$773K |
| 3 |
Gartner
IT
|
$769K |
| 4 |
Quanta Services
PWR
|
$762K |
| 5 |
Trane Technologies
TT
|
$759K |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$854K |
| 2 |
Arthur J. Gallagher & Co
AJG
|
$778K |
| 3 |
IDEX
IEX
|
$731K |
| 4 |
Tesla
TSLA
|
$719K |
| 5 |
VICI Properties
VICI
|
$715K |
Sector Composition
| 1 | Healthcare | 22.36% |
| 2 | Technology | 15.51% |
| 3 | Financials | 14.54% |
| 4 | Industrials | 9.65% |
| 5 | Energy | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAGE
201
DELISTED
Sage Therapeutics
SAGE
| $333K | 0.21% |
15,380
+10,140
| +194% | +$220K |
|
202
Theravance Biopharma
TBPH
$703M
| $333K | 0.21% |
29,628
+396
| +1% | +$4.45K |
|
203
Sarepta Therapeutics
SRPT
$1.96B
| $333K | 0.21% |
3,451
+1,117
| +48% | +$108K |
|
|
DCPH
204
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $332K | 0.21% |
20,606
-854
| -4% | -$13.8K |
|
205
Ionis Pharmaceuticals
IONS
$9.76B
| $331K | 0.21% |
6,548
-909
| -12% | -$46K |
|
206
BioNTech
BNTX
$27B
| $331K | 0.21% |
3,138
+398
| +15% | +$42K |
|
207
Biogen
BIIB
$20.6B
| $329K | 0.21% |
1,272
+256
| +25% | +$66.2K |
|
208
Roivant Sciences
ROIV
$8.82B
| $329K | 0.21% |
29,308
-2,030
| -6% | -$22.8K |
|
209
Ironwood Pharmaceuticals
IRWD
$188M
| $326K | 0.21% |
28,489
+951
| +3% | +$10.9K |
|
210
Amylyx Pharmaceuticals
AMLX
$910M
| $326K | 0.21% |
22,130
+9,907
| +81% | +$146K |
|
211
PTC Therapeutics
PTCT
$4.55B
| $326K | 0.21% |
11,819
+4,744
| +67% | +$131K |
|
212
Aurinia Pharmaceuticals
AUPH
$1.63B
| $325K | 0.21% |
36,124
+5,267
| +17% | +$47.4K |
|
213
CRISPR Therapeutics
CRSP
$4.99B
| $324K | 0.21% |
5,183
+3,502
| +208% | +$219K |
|
214
Gilead Sciences
GILD
$143B
| $323K | 0.21% |
3,989
+48
| +1% | +$3.89K |
|
215
BioMarin Pharmaceuticals
BMRN
$11.1B
| $322K | 0.2% |
3,342
+121
| +4% | +$11.7K |
|
216
Incyte
INCY
$16.9B
| $321K | 0.2% |
5,110
+159
| +3% | +$9.98K |
|
217
Legend Biotech
LEGN
$6.66B
| $320K | 0.2% |
5,314
+905
| +21% | +$54.5K |
|
|
ONC
218
BeOne Medicines Ltd. American Depositary Shares
ONC
$37.6B
| $314K | 0.2% |
1,739
+280
| +19% | +$50.5K |
|
219
Agios Pharmaceuticals
AGIO
$2.09B
| $313K | 0.2% |
14,036
+2,213
| +19% | +$49.3K |
|
220
Harmony Biosciences
HRMY
$2.07B
| $312K | 0.2% |
9,657
+1,147
| +13% | +$37K |
|
221
Gladstone Investment Corp
GAIN
$543M
| $311K | 0.2% |
21,997
-15,634
| -42% | -$221K |
|
222
Halozyme
HALO
$8.76B
| $306K | 0.19% |
8,269
-962
| -10% | -$35.6K |
|
223
BioCryst Pharmaceuticals
BCRX
$1.74B
| $304K | 0.19% |
50,731
+12,410
| +32% | +$74.3K |
|
224
Invesco Quality Municipal Securities
IQI
$507M
| $303K | 0.19% |
31,868
-13,249
| -29% | -$126K |
|
225
OFS Capital
OFS
$117M
| $297K | 0.19% |
25,347
-8,197
| -24% | -$95.9K |
|